DRUG FOR USE AGAINST THE NOVEL CORONAVIRUS DISEASE, COVID-19

摘要

The invention concerns a medicinal drug effective for the treatment of COVID-19 disease caused by the SARS-Cov-2 virus and preventing the development of its dangerous complications associated with pulmonary edema. For this purpose, a drug is proposed comprising aprotinin as a pharmaceutically active component in the form of a dry powder aerosol with a particle size of less than 1.0 μm. Such a drug provides the possibility of targeted delivery of aprotinin to the lower respiratory tract and alveoli, which makes it possible to influence both the etiology (due to the antiviral effect of aprotinin) and the pathogenesis of COVID-19 disease (due to the anti-inflammatory effect of aprotinin) directly in the focus of the pathologic pathway.